IGF1R and thymoma: A phase II study of cixutumumab, an IGF-1R monoclonal antibody, in 49 patients with previously treated advanced thymic tumors showed limited activity in thymoma (ORR 14%, 95% CI 5–29%) and no effectiveness in TC (ORR 0%, 95% CI 0–26%) [23].